Current Surgical Perspective on the Prognosis of Small-Cell Lung Cancer

Area of Science:

• Oncology
• Thoracic Surgery
• Cancer Research

Background:

• Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with early metastasis and treatment resistance.
• Smoking is a primary risk factor, linked to duration of use, with ~95% of patients having a smoking history.
• Current treatments, including chemotherapy (CT) and radiotherapy (RT), offer limited survival benefits.

Purpose of the Study:

• To investigate the prognosis and prognostic factors of SCLC from a surgical perspective.
• To review current literature and identify trends for personalized treatment approaches in SCLC.
• To highlight the limited research, particularly surgical case series, on SCLC prognosis.

Main Methods:

• Literature review of current studies on SCLC prognosis and treatment.
• Analysis of survival data, including overall survival (OS) and stage-specific five-year survival rates.
• Examination of the role of surgery, chemotherapy, radiotherapy, and emerging immunotherapies.

Main Results:

• Surgical resection is feasible for early-stage SCLC, with OS ranging from 34-69 months.
• Five-year survival rates vary significantly by stage (Stage I: 31-63.8%, Stage IV: 0%).
• Immunotherapy shows promise but currently offers limited survival gains (~2 months).

Conclusions:

• Despite advances, SCLC prognosis remains poor, necessitating personalized treatment strategies.
• Early-stage SCLC management may involve resection followed by chemotherapy.
• Further research, especially surgical studies, is crucial for improving SCLC outcomes.